Research programme: hepatitis B therapeutics - Janssen Pharmaceuticals/Chia Tai Tianqing
Latest Information Update: 19 Jan 2016
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Immunotherapies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Hepatitis B
Most Recent Events
- 07 Jan 2016 Early research in Hepatitis B in China (unspecified route)